Track topics on Twitter Track topics that are important to you
Clingenix, Inc. was founded in 1998 by leading scientists from Harvard, Stanford, and private industry to provide pharmacogenomic as well as conventional research, development and application services to the drug development and medical device industries. The founders are experts in the fields of medicine, genetics, clinical trials, and information technology. The Company is headquartered in Sunnyvale, California with operations through out the US, Taiwan and the Asia Pacific Region. The company provides a full range of services from developmental consulting, through all phases of clinical development, to commercialization.
The mission of the Company is to be the premiere pharmacogenomics company offering a full range of genomic based research, development and application services and diagnostic products for monitoring diseases and disease progression to pharmaceutical, biotechnology, medical device, and diagnostic companies for drug development and commercialization.
Clingenix provides pharmacogenomics services and diagnostic products in the therapeutic areas of diabetes, insulin resistance, hypertension, oncology, cardiovascular and atherosclerosis. The company is currently expanding to other therapeutic areas using the initial template.
Clingenix's management believes that the application of pharmacogenomics knowledge coupled with traditional discovery and developmental processes to drug development will reduce clinical trial costs, shorten the drug development cycle, improve new drugs approval rate and market positioning, rescue drugs that will or have failed clinical trial or FDA approval, and improve trial predictability. These outcomes are possible because
pharmacogenomics allows for better targeting, higher efficacy, and lower toxicity of new drugs.
The Company services provide for many commercial advantages in medicine, and diagnostics. Clingenix enjoys a decisive market advantage over its competitors through existing capabilities in Asia. Advantages include extensive access to investigators and patients, ownership of biological materials from type 2 diabetes, ownership of a database in the insulin resistant and hypertension therapeutic areas, and world renown technical expertise in these therapeutic areas. The database contains genotype, phenotype, and metabolic data, total genome scan with over 300 markers, and immortal cell lines. Putative loci linked to resistance and dyslipidemia have also been identified.
Clingenix collaborates with academic and industrial leaders in pharmaceuticals, diagnostics, biotechnology, and medical instrumentation.
Based on a strong foundation in medicine, genomics, clinical trials, and information technology, Clingenix promises to be the premiere provider of pharmacogenomics services and products.
1190 Bordeaux Drive
United States of America
Phone: (408) 752-1635
Fax: (408) 752-0347
MENLO PARK, CA -- (Marketwired) -- 05/04/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that tre...
LIVINGSTON, NJ --(Marketwired - September 14, 2017) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a medical company that develops and commercializes a growing portfolio of propri...
Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...
Clingenix, Inc. was founded in 1998 by leading scientists from Harvard, Stanford, and private industry to provide pharmacogenomic as well as conventional research, development and application services...
PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...
Founded in 2008 by the Axis Biotec Brasilâ¢ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....
COOK SIS is sold under various brand names to treat a wide range of conditions including management of dermal wounds and burns, reinforcement of many types of weakened tissue, and treatment of urinary...
Founded by Conrad Kenley in 1990, LCG, Inc. is a leader in providing grants management solutions to health and social services agencies. LCG Systems (a subsidiary of LCG, Inc.) ...
We have published hundreds of Clingenix Incorporated news stories on BioPortfolio along with dozens of Clingenix Incorporated Clinical Trials and PubMed Articles about Clingenix Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Clingenix Incorporated Companies in our database. You can also find out about relevant Clingenix Incorporated Drugs and Medications on this site too.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...